anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCNL (Percutaneous Nephrolithotomy) is the preferred treatment option for kidney stones with a diameter of ≥ 2 cm . Hemorrhage and infection are the primary complications following PCNL. Thanks to the advancements in interventional techniques, most hemorrhagic complications can be controlled with interventional treatment. In contrast, related infectious complications, such as urosepsis, are more perilous and challenging to control. Therefore, measures should be taken to prevent the occurrence of post-PCNL infectious complications, among which the most critical is the use of perioperative antibiotics. Currently, there is no consensus in the academic community regarding the strategy for the use of perioperative antibiotics in patients with positive preoperative urine cultures undergoing PCNL , and there is controversy over whether it is necessary to recheck urine culture after treatment with sensitive antibiotics . Some scholars believe that urine culture should be rechecked after antibiotic treatment and surgery should be performed only after the culture turns negative , but others argue that it is unnecessary to recheck urine culture after antibiotic treatment . Generally, since antibiotics might induce false-negative results in urine bacteria, it is recommended to discontinue antibiotics for more than 3 days before re-examining the urine culture . However, urological patients often have stone obstruction combined with urinary tract infection, and discontinuing antibiotics might lead to the recurrence of the infection. Therefore, this article mainly explores the role of re-examined urine culture after treatment with sensitive antibiotics in predicting infectious complications related to mini-PCNL post-surgery.
Summary Formulation and method for the prevention and treatment of skeletal manifestation of Gaucher's disease The invention relates to the prevention and treatment of skeletal manifestation of Gaucher's disease. It relates to a formulation for introducing glucocerebrosidase into the lysosomal compartment of macrophages and/or Gaucher cells in the bone marrow, the formulation comprising glucocerebrosidase encapsulated in erythrocytes. Said erythrocytes may have been subjected to a chemical treatment with an agent so as to promote the targeting of macrophages and/or Gaucher cells in the bone marrow. The treatment may be carried out with a bis(sulphosuccinimidyl) suberate (BS3) solution. The invention also describes drugs and methods for prevention and treatment. No figures.
The present invention relates to the treatment of CMV related diseases. In a rat model of CMV infection of the developing brain in utero, the inventors recently detected prominent infection of brain immune cells and early neuroimmune defects at the cellular and molecular levels. Severe postnatal phenotypes reminiscent of the human disease (e.g. epileptic seizures, altered sensorimotor development) the inventors observed in the first postnatal weeks. At the molecular level, they now have investigated the pathophysiological role of the chemokine rl29, encoded by the rat CMV genome (used as a proof of concept) and that showed very early RNA expression in RCMV-infected fetal brains. Co-infection experiments of the developing brain in utero with wild-type (wt) RCMV and with its mutant RCMV counterpart encoding a dominant- negative r129 isoform dramatically rescued the severe postnatal phenotypes caused by wt RCMV alone. Furthermore, sequential infection with the two viruses, starting with in utero injection at E14 of RCMV encoding the dominant-negative r129 isoform, then followed 24h apart by in utero injection at E15 of the wt RCMV, also led to dramatic rescue of the postnatal phenotypes. Importantly, injection of only the RCMV encoding the dominant-negative r129 isoform did not lead to any of the postnatal phenotypes observed with the wt RCMV. Thus, the use of an inhibitor of EIL128 (e.g. the use of a dominant-negative, inhibitory isoform of EIL128), the human CMV (hCMV) analogue of r129, will have the same benefit on CMV related diseases. Thus, the present invention relates to an ETL128 inhibitor for use in the treatment and prevention of CMV related diseases in a subject in need thereof.
Patients with distal rectal adenocarcinoma will be submitted to an initial whole body PET/CT prior to the preoperative chemoradiation therapy with 5-fluorouracil and 5040 cGy. Six weeks and 12 weeks after the preoperative treatment is finished the PET/CT will be repeated. At 1 and at 2 years after preoperative treatment is concluded another PET/CT will be performed. The colorectal surgeon evaluating the response to chemoradiation therapy will be blinded to the results of the PET/CT, as the radiologist will be blinded to the response assessment. PET/CT results will not be used to determine treatment strategy, unless metastatic disease or other disease is diagnosed. Patients with a complete clinical response at 8 weeks will be rigorously followed while patients with an incomplete clinical response at 8 weeks will be submitted to radical surgery. PET/CT results will be compared to current radiological studies and final pathological reports.
Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
Subarachnoid hemorrhage (SAH) due to the rupture of an intracranial aneurysm leads to delayed vasospasm and neuroischemia, which can result in profound neurologic deficit and death. Therapeutic options after SAH are currently limited to hemodynamic optimization and nimodipine, which have limited clinical efficacy. Experimental SAH results in cerebral vasospasm have demonstrated the downregulation of nitric oxide (NO)-protein kinase G (PKG) signaling elements. VP3 is a novel cell permeant phosphopeptide mimetic of VASP, a substrate of PKG and an actin-associated protein that modulates vasorelaxation in vascular smooth muscle cells. In this study, we determined that intravenous administration of high doses of VP3 did not induce systemic hypotension in rats except at the maximal soluble dose, implying that VP3 is well-tolerated and has a wide therapeutic window. Using a single cisterna magna injection rat model of SAH, we demonstrated that intravenous administration of low-dose VP3 after SAH improved neurologic deficits for up to 14 days as determined by the rotarod test. These findings suggest that strategies aimed at targeting the cerebral vasculature with VP3 may improve neurologic deficits associated with SAH.
Respondent are health workers that is having mild to moderate anxiety symptoms, with Hamilton Anxiety Scale less than 25. This arm will receive 3 acupuncture treatment within 2 weeks, and will be taken outcome measurements 4 times, that is before the first needle placement, after replacing the first sets of needles, after removing the third sets of needles and at 2 weeks after removing the third sets of needle.
Subjects will complete a baseline eucaloric study day. Following this, subjects will be randomized to complete 3 days of overfeeding (150% of baseline eucaloric energy requirements) or 3 days of underfeeding (50% of baseline eucaloric energy requirements). After completing one of these study arms, subjects will cross-over and complete the second arm. All study arms will be separated by two weeks. 24-hour energy expenditure will be measured 3 times during each of 3 day periods. We hypothesize that the impact of over or underfeeding on EE will be evident after 24-hours and will be comparable to 72 hour EE.
In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation \< 2x pacing threshold), implantation of a HIS-pacing lead is attempted instead. If that is not possible or the threshold for correcting the LBBB is \> 2.5 V at 1 ms, implantation of a LBB-pacing lead is attempted instead.
A personalization assist system for a user of a vision correction device includes a remote computing unit with a controller having a processor and a tangible, non-transitory memory having instructions recorded thereon. The controller is configured to selectively execute one or more machine learning models. A user device is operable by the user and includes an electronic log module configured to prompt the user at specific intervals to answer one or more preselected questions. The electronic log module is configured to store respective answers entered by the user in response to the one or more preselected questions as self-reporting data. The controller is configured to obtain the self-reporting data from the electronic log module and generate an analysis of the self-reporting data via the one or more machine learning models. The controller is configured to assist the user based in part on the analysis.
BACKGROUND: Candida auris was sporadically detected in Greece until 2019. Thereupon, there has been an increase in isolations among inpatients of healthcare facilities.
AIM: We aim to report active surveillance data on MALDI-TOF confirmed Candida auris cases and outbreaks, from November 2019 to September 2021.
METHODS: A retrospective study on hospital-based Candida auris data, over a 23-month period was conducted, involving 11 hospitals within Attica region. Antifungal susceptibility testing and genotyping were conducted. Case mortality and fatality rates were calculated and p-values less than 0.05 were considered statistically significant. Infection control measures were enforced and enhanced.
RESULTS: Twenty cases with invasive infection and 25 colonized were identified (median age: 72 years), all admitted to hospitals for reasons other than fungal infections. Median hospitalisation time until diagnosis was 26 days. Common risk factors among cases were the presence of indwelling devices (91.1 %), concurrent bacterial infections during hospitalisation (60.0 %), multiple antimicrobial drug treatment courses prior to hospitalisation (57.8 %), and admission in the ICU (44.4 %). Overall mortality rate was 53 %, after a median of 41.5 hospitalisation days. Resistance to fluconazole and amphotericin B was identified in 100 % and 3 % of tested clinical isolates, respectively. All isolates belonged to South Asian clade I. Outbreaks were identified in six hospitals, while remaining hospitals detected sporadic C. auris cases.
CONCLUSION: Candida auris has proven its ability to rapidly spread and persist among inpatients and environment of healthcare facilities. Surveillance focused on the presence of risk factors and local epidemiology, and implementation of strict infection control measures remain the most useful interventions.
Experimental group II receives 8 weeks of routine health care of constipation first, then interventions are stopped for two month as residual effect wash-out period. And after that Experimental group II receives 8 weeks of auricular acupressure .
The HVTN 073/SAAVI 102 study is evaluating the safety of two experimental HIV vaccines-SAAVI DNA-C2 and SAAVI MVA-C-given sequentially as a prime-boost regimen in healthy, HIV-uninfected adults. This is an extension of that study and will enroll people who participated in the HVTN 073/SAAVI 102 study. Previous studies have shown that a protein vaccine boost to an HIV vaccine may improve antibody responses. This study will evaluate the safety and immune response to an HIV envelope protein vaccine-the Sub C gp140 vaccine with MF59 adjuvant-in healthy, HIV-uninfected adults who have previously participated in the HVTN 073/SAAVI 102 study. Study researchers will explore whether the addition of a protein boost vaccine to the SAAVI DNA-C2 and SAAVI MVA-C vaccine regimen improves antibody response.

This study will enroll people who participated in the HVTN 073/SAAVI 102 study,regardless of whether they received vaccine or placebo. Participants will be randomly assigned to receive either the Sub C gp140 vaccine with MF59 adjuvant or a placebo injection during study visits at baseline and Month 3. At the baseline and Month 3 visits, participants will undergo a physical examination, HIV testing and counseling, pregnancy testing for female participants, interviews and questionnaires, risk reduction counseling, and blood collection (at the baseline visit only). They will then receive their assigned vaccine or placebo as one injection in their upper arm. Participants will remain in the clinic for 30 minutes after receiving the vaccination for observation and monitoring. For 3 days after the vaccination, participants will record any side effects in a symptom log and make contact daily with the study site staff.

Additional study visits will occur at Weeks 1 and 2, 1 and 2 weeks after the Month 3 visit, and Months 6 and 9. At these visits, select baseline study procedures will occur. At Month 15, study staff will contact participants for follow-up health monitoring. Participants will then complete any annual health contacts for the original HVTN 073/SAAVI 102 study.
PURPOSE:To prepare a chewing dentifrice having improved adhesivity to the teeth and bitability, and effective to clean the teeth and increase the occlusal force, by mixing a fibrous substance to a gum base composed of natural chicle, natural resin and vinyl acetate resin, etc. CONSTITUTION:A gum base composed of natural chicle, natural resin and vinyl acetate resin, etc. is mixed with a natural or synthetic fibrous material such as hemp fiber, Japanese paper, or fibrous material constituting Japanese paper. The adhesivity of the gum base can be lowered, and sufficient tooth-polishing effect can be attained because the gum is liable to slip on the surface of the tooth owing to the lowered adhesivity. Since the gum is resistant to be bitten off, high occlusal force is generated between the upper teeth and the lower teeth. The muscle of the jaw and the growth of the maxillary bone can be fortified by the continuous use of the dentifrice. A drug action is expected by adding conventional toothpaste or various drugs to the dentifrice. It can be used at any time anywhere without necessitating water, easily, even by children.
The invention relates to a composition having a therapeutic activity, to the use of the composition, and to a method for producing the same. The aim of the invention is to create a therapeutic agent, particularly for therapeutically treating psora (psoriasis) and hair loss, which does not result in any cytotoxic effect while exhibiting a good activity and, in addition, has essentially no miscellaneous side-effects. To this end, the inventive composition having a therapeutic activity is comprised of constituents extracted from the plant Plumbago europaea and of at least one additional constituent of natural origin. The constituents extracted from Plumbago europaea in conjunction with additional constituents of natural origin, e.g. dairy products or garlic extract, exhibit a distinct therapeutic effect when externally applied without any undesired side-effects with the exception of temporary skin irritations at the beginning of treatment. Absolutely no cytotoxic effects are observed due to the natural origin of the composition.
A preparation method of porous hollow calcium carbonate drug-loaded microspheres comprises the following steps: (1) culturing of microbial cells: adding the strain into liquid culture mediumTaking the precipitate, and placing the precipitate in a NaCl solution for re-suspension for later use; (2) preparing a layer-by-layer self-assembly coating on the surface of a strain: and (3) alternately adding polydiene dimethyl ammonium chloride solution and polystyrene sulfonic acid solution into the bacteria to obtain the bacterial cells coated with surface polyelectrolyte. (3) Calcium salt pretreatment: adding Ca to strain cells 2+ The solution was magnetically stirred and mixed well. (4) Preparing a calcium carbonate shell: adding the same amount of CO dropwise into the solution 3   2‑ The solution was magnetically stirred for 16 h. The resulting mixture was repeatedly washed with pure water, and then dried and ground. Thus obtaining the nano calcium carbonate shell on the surface of the strain cell. (5) Preparing porous hollow calcium carbonate microspheres: and (3) putting the nano calcium carbonate shell particles into a tube furnace, and removing strain cells in the inner layer to obtain the hollow porous calcium carbonate microspheres. The invention has low cost and simple preparation process.
This is a prospective, multi-center study. Subjects with OSCC or OPSCC will be enrolled from four primary and secondary care centers in the U.S. Study samples will be collected by the clinicians at the study sites using Viome saliva sample collection kits. Patients will continue with their current health plan and confirm diagnosis following the standard of care of surgical biopsy with histology if needed. If a biopsy is performed, the result of the biopsy will be compared with the result of the Viome kit. If no biopsy is performed, the Viome test result will be compared with the physician's assessment based on clinical judgment. Patients with a positive result from histology will not receive the results of the Viome kit, and it will not play any part in the clinical management of the patients.
First placement of the sheath and successful passage of a 0.018" or 0.035" guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter.
BACKGROUND: Colorectal cancer (CRC) is a major cause of mortality and morbidity. A study proved that brexpiprazole, as a novel dopamine receptor partial agonist, can also prevent CRC cell proliferation. Therefore, clarifying the molecular mechanism of brexpiprazole is vital to developing a novel therapeutic strategy for CRC.
METHODS: The effect of brexpiprazole on human colorectal cancer cell proliferation was measured with Cell Counting Kit-8 (CCK-8) kits. Cell migration capability was measured using wound healing and transwell. Cell apoptosis was evaluated with a flow cytometer. Western blots and immunohistochemical staining were used to evaluate protein expression. The effects observed in vitro were also confirmed in xenograft models.
RESULTS: Brexpiprazole remarkably inhibited the proliferation, suppressed the migration ability, and induced apoptosis of colorectal cancer cells. Mechanism study showed that brexpiprazole exerted these effects by inhibiting the EGFR pathway. Brexpiprazole enhanced HCT116 cells' sensitivity to cetuximab, and a combination of brexpiprazole and cetuximab inhibited xenograft tumor growth in vivo.
CONCLUSIONS: Our finding suggested that brexpiprazole inhibits proliferation, promotes apoptosis, and enhances CRC cells' sensitivity to cetuximab by regulating the EGFR pathway and it might be an efficacious treatment strategy for CRC.
PURPOSE:To use safely protein polysaccharide, especially krestin well-known as an antitumor agent derived from Basidiomyces belonging to the genus Coriolus versicolor as an antirheumatic agent by its inhibitory action on adjuvant arthritis, improving action on pain, grasping power, etc. CONSTITUTION:Protein polysaccharide, especially krestin, an extract of cultivated mycelium or fruit body of Basidiomyces belonging to the genus Coriolus versicolor with hot water or an alkali solution, containing about 18-38wt% protein, 5,000-300,000 molecular weight (ultracentrifugation method) is used as an antirheumatic agent. Crestin is well-known as an antitumor agent, it is found to have further an inhibitory action on adjuvant arthritis, improving action on pain, grasping power, etc., and to be useful as antirheumatic agent. Besides, it has low toxicity and almost no side effect. It is preferably medicated by oral administration. A dose is preferably 20-600mg/kg/day.
Metabolism and Excretion

The fatty acids, phospholipids, and glycerol found in lipid emulsions are metabolized by cells to carbon dioxide and water. The metabolism of these substances results in the generation of energy in the form of adenosine triphosphate (ATP). Some fatty acids are stored in the body in fat tissue, cell membranes, or as intracellular triglycerides. There is constant turn-over of these tissues, with the result that the lipid components are eventually metabolized to carbon dioxide and water. Carbon dioxide is expired through the lungs. Water is excreted through the kidneys or lost through evaporation/expiration through the skin, lungs, and other tissue surfaces. Some lipids (i.e., phospholipids, cholesterol, and bile acids) are excreted through the biliary system.
Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
Fluid balance charts are commonly used, in the Netherlands, to assess patient fluid volume status. Some disadvantages of recording fluid intake and output are that it is time-consuming and complex. If it would give reliable and accurate information about the fluid volume status there would be a good reason for all this effort. In the few researches that have investigated this subject a low correlation has been found between the fluid balance and the weight changes of an adult patient. Own experience gives reasons to doubt about the reliability of the fluid balance in children, not rarely there is a discrepancy between the fluid balance and the weight measurement. We are interested in the relevance of recording fluid balance in neonates.